Literature DB >> 22619646

Does Radiotherapy Have Curative Potential in Metastatic Patients? The Concept of Local Therapy in Oligometastatic Breast Cancer.

Kathrin Dellas1.   

Abstract

In 1995, Hellmann and Weichselbaum defined for the first time the term oligometastases which is used to describe limited metastasis with a maximum of 3-4 clinically detectable metastases. It is assumed that these patients have a better prognosis and that local treatment of the metastases plays a significant part in the further development of the disease. Therefore, these patients could benefit from a curative local therapy of the manifested metastases. Local therapy measures include mainly radiotherapeutic methods alongside invasive ablative processes, such as surgical resection and radiofrequency ablation. Patients subjected to radiation therapy benefit especially from the usage of modern precision technology as it reduces the radiation exposure to the normal tissue, and because short radiation sessions with escalating doses are possible (e.g. radiation surgery, image-assisted radiation therapy, stereotactic radiation). Initial clinical studies show very good local tumor control rates which are on a par with resection and ablative methods, but with very few side effects and risks. This article summarizes the integration of the concept of oligometastases in the radiotherapy of limited metastatic breast cancer.

Entities:  

Year:  2011        PMID: 22619646      PMCID: PMC3357150          DOI: 10.1159/000333115

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  45 in total

1.  Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen.

Authors:  D E Wazer; O F Tercilla; P S Lin; R Schmidt-Ullrich
Journal:  Br J Radiol       Date:  1989-12       Impact factor: 3.039

Review 2.  Stereotactic body radiation therapy for extracranial oligometastases: does the sword have a double edge?

Authors:  Madeleine Carey Sampson; Alan Katz; Louis S Constine
Journal:  Semin Radiat Oncol       Date:  2006-04       Impact factor: 5.934

Review 3.  The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate.

Authors:  S A Leibel; M J Zelefsky; G J Kutcher; C M Burman; R Mohan; G S Mageras; C C Ling; Z Fuks
Journal:  Semin Oncol       Date:  1994-10       Impact factor: 4.929

Review 4.  Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria.

Authors:  S Burdach; B van Kaick; H J Laws; S Ahrens; R Haase; D Körholz; H Pape; J Dunst; T Kahn; R Willers; B Engel; U Dirksen; C Kramm; W Nürnberger; A Heyll; R Ladenstein; H Gadner; H Jürgens; U Go el
Journal:  Ann Oncol       Date:  2000-11       Impact factor: 32.976

5.  Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro.

Authors:  G H Paulsen; T Strickert; A B Marthinsen; S Lundgren
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

6.  Effect of conjoint administration of tamoxifen and high-dose radiation on the development of mammary carcinoma.

Authors:  D A Kantorowitz; H J Thompson; P Furmanski
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-04-30       Impact factor: 7.038

7.  Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence.

Authors:  K S Hughes; R Simon; S Songhorabodi; M A Adson; D M Ilstrup; J G Fortner; B J Maclean; J H Foster; J M Daly; D Fitzherbert
Journal:  Surgery       Date:  1986-08       Impact factor: 3.982

8.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

9.  Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines.

Authors:  C Cillo; J E Dick; V Ling; R P Hill
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

10.  STAT1 pathway mediates amplification of metastatic potential and resistance to therapy.

Authors:  Nikolai N Khodarev; Paul Roach; Sean P Pitroda; Daniel W Golden; Mihir Bhayani; Michael Y Shao; Thomas E Darga; Mara G Beveridge; Ravi F Sood; Harold G Sutton; Michael A Beckett; Helena J Mauceri; Mitchell C Posner; Ralph R Weichselbaum
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

View more
  5 in total

1.  The Challenge of Integrating Radiotherapy in the Multimodal Treatment of Breast Cancer.

Authors:  Rainer Souchon; Juergen Dunst
Journal:  Breast Care (Basel)       Date:  2011-10-31       Impact factor: 2.860

2.  The role of SBRT in oligometastatic patients with liver metastases from breast cancer.

Authors:  Marta Scorsetti; Davide Franceschini; Fiorenza De Rose; Tiziana Comito; Ciro Franzese; Giovanna Masci; Rosalba Torrisi; Luca Viganò; Guido Torzilli
Journal:  Rep Pract Oncol Radiother       Date:  2016-09-05

Review 3.  Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?

Authors:  Simona Di Lascio; Olivia Pagani
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

4.  Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy.

Authors:  Gyu Sang Yoo; Jeong Il Yu; Won Park; Seung Jae Huh; Doo Ho Choi
Journal:  Radiat Oncol J       Date:  2015-12-30

5.  Assessment of Radiation Induced Therapeutic Effect and Cytotoxicity in Cancer Patients Based on Transcriptomic Profiling.

Authors:  Sajjad Karim; Zeenat Mirza; Adeel G Chaudhary; Adel M Abuzenadah; Mamdooh Gari; Mohammed H Al-Qahtani
Journal:  Int J Mol Sci       Date:  2016-02-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.